Reports Q4 revenue $30.0M, consensus $26.9M. "2022 was an important year for Heron, highlighted by the expansion of our acute care franchise to cover the two most common concerns for patients and clinicians after surgery, pain and nausea and vomiting. We were thrilled with the approval and recent launch of our fourth commercial product, APONVIE, for PONV, and remain encouraged with the continued growth of ZYNRELEF sales even in a quarter where seasonal declines are anticipated," said CEO Barry Quart. "In our oncology care franchise, we saw strong growth, exceeding our full-year 2022 guidance with $97.5M in net product sales. In addition, the significant reduction in cost of goods for CINVANTI achieved in Q4 will have an important impact on reducing cash burn in 2023 and beyond."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HRTX:
- Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
- Heron announces CMS granted pass-through payment status for APONVIE
- Heron says CMS granted pass-through payment status for Aponvie
- Heron Therapeutics announces U.S. commercial launch of APONVIE
- Heron Therapeutics announces cooperation agreement with Rubric and Velan
